Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.370 -0.010 (-0.19%)
Streaming Delayed Price Updated: 3:38 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
Via Stocktwits
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion. 
Via Stocktwits
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity. 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
A Look Ahead: MannKind's Earnings Forecast
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
MannKind's Earnings Outlook
 
Via Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals. 
Via Stocktwits
MannKind (MNKD) Q2 Revenue Rises 6%
Via The Motley Fool
Topics Intellectual Property World Trade
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market
MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer... 
Via Chartmill
Topics Earnings
Top 3 Health Care Stocks That May Rocket Higher This Quarter
 
Via Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and... 
Via Stocktwits
MannKind (MNKD) Q4 2024 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Topics Stocks
MannKind Shares Are falling Today: What's Going On?
MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here's what you need to know. 
Via Benzinga
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
MannKind (MNKD) Q2 2024 Earnings Call Transcript
MNKD earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Our first-ever twin bill. 
Via The Motley Fool
MannKind (MNKD) Q1 2024 Earnings Call Transcript
MNKD earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.